AstraZeneca to test Sputnik V component in clinical trials of AZD1222, its own vaccine

11 December 2020

UK and Russian scientists are teaming up to trial a combination of the Oxford University-developed COVID-19 vaccine with Sputnik V vaccines to see if protection against the novel coronavirus can be improved.

After the Sputnik V vaccine’s clinical trial preliminary results showed its efficacy at above 90%, the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) and Gamaleya Institute on November 23, offered UK pharma major AstraZeneca (LSE: AZN) the use one of the two components (human adenoviral vectors of the Sputnik V in AstraZeneca’s own COVID-19 vaccine clinical trials.

AstraZeneca has confirmed it has accepted RDIF’s proposal and will begin clinical trials of its AZD1222 vaccine in combination with Sputnik V’s human adenoviral vector type Ad26 by the end of 2020. This research will allow AstraZeneca’s scientists to study the possibility of boosting their vaccine’s efficacy through the application of this combined approach.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK